Interim Results of the Phase III Portal Extension Trial of the Port Delivery System with Ranibizumab in Neovascular Age-Related Macular Degeneration
Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Authors
- W. Lloyd Clark
- Margaret Chang
- Shamika Gune (ORCID: https://orcid.org/0000-0001-9963-5652)
- David Eichenbaum (ORCID: https://orcid.org/0000-0003-0654-0668)
- Natasha Singh (ORCID: https://orcid.org/0000-0002-5130-9679)
- Sophie Le Pogam
- Melina Cavichini Cordeiro
- Jordan M. Graff
- Stephanie Lin
- Peter A. Campochiaro (ORCID: https://orcid.org/0000-0003-2531-8229)
- Natalia F. Callaway (ORCID: https://orcid.org/0000-0002-9788-9605)
- Mel Rabena
Institutions
- Johns Hopkins University (US)
- University of South Florida (US)
- Johns Hopkins Medicine (US)
- California Retina Consultants (US)
- Retinal Consultants of Arizona (US)
- Palmetto Retina Center (US)
- Retina Vitreous Associates of Florida (US)
- Smith-Kettlewell Eye Research Institute (US)
- Smith-Kettlewell Eye Research Institute (US)
- Stanford University (US)
Publication Details
- Journal
- Ophthalmology Retina
- Published
- 2024-08-30
- DOI
- https://doi.org/10.1016/j.oret.2024.05.021
- Citations
- 7
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.77
Funders
- Genentech